Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristian Reich

Showing results (191-200 of 217) with videos related to

Pageof 22
Sort By:
Journal of the American Academy of Dermatology|July 21, 2022
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trialAndrew Blauvelt, Richard G Langley, Jean-Philippe Lacour, et al.
Dermatology and Therapy|November 22, 2019
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of ExposureApril Armstrong, Carle Paul, Luis Puig, et al.
Dermatology and Therapy|February 5, 2026
Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTENDAndrew Blauvelt, H Chih-Ho Hong, Norito Katoh, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 28, 2019
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasisRichard G B Langley, Kristian Reich, Vibeke Strand, et al.
JAMA Dermatology|October 1, 2020
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical TrialKristian Reich, Kenji Kabashima, Ketty Peris, et al.
The British Journal of Dermatology|August 29, 2025
Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of 8 clinical trialsKristian Reich, Richard G Langley, Juan Francisco Silvestre Salvador, et al.
Dermatology and Therapy|March 23, 2020
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled TrialsCraig Leonardi, Kristian Reich, Peter Foley, et al.
Acta Dermato-Venereologica|February 11, 2022
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance DataAlice B Gottlieb, Atul Deodhar, Iain B Mcinnes, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 19, 2023
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND studyKristian Reich, Jonathan I Silverberg, Kim A Papp, et al.
Lancet (London, England)|June 15, 2015
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsChristopher E M Griffiths, Kristian Reich, Mark Lebwohl, et al.
Pageof 22

Showing results (191-200 of 217) with videos related to

Sort By:
Pageof 22
Journal of the American Academy of Dermatology|July 21, 2022
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trialAndrew Blauvelt, Richard G Langley, Jean-Philippe Lacour, et al.
Dermatology and Therapy|November 22, 2019
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of ExposureApril Armstrong, Carle Paul, Luis Puig, et al.
Dermatology and Therapy|February 5, 2026
Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTENDAndrew Blauvelt, H Chih-Ho Hong, Norito Katoh, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 28, 2019
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasisRichard G B Langley, Kristian Reich, Vibeke Strand, et al.
JAMA Dermatology|October 1, 2020
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical TrialKristian Reich, Kenji Kabashima, Ketty Peris, et al.
The British Journal of Dermatology|August 29, 2025
Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of 8 clinical trialsKristian Reich, Richard G Langley, Juan Francisco Silvestre Salvador, et al.
Dermatology and Therapy|March 23, 2020
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled TrialsCraig Leonardi, Kristian Reich, Peter Foley, et al.
Acta Dermato-Venereologica|February 11, 2022
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance DataAlice B Gottlieb, Atul Deodhar, Iain B Mcinnes, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 19, 2023
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND studyKristian Reich, Jonathan I Silverberg, Kim A Papp, et al.
Lancet (London, England)|June 15, 2015
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsChristopher E M Griffiths, Kristian Reich, Mark Lebwohl, et al.
Pageof 22